Real-life treatment patterns, compliance, persistence, and medication costs in patients with hypertension in Germany

Journal of Medical Economics

Volumn 15, Issue 1, 2012, Pages 155-165

  Breitscheidel, L ^a   Ehlken, B ^a   Kostev, K ^a   Oberdiek, M S A ^b   Sandberg, A ^b   Schmieder, R E ^c  

^a IQVIA   (United States)

^b DAIICHI SANKYO CO   (Japan)

^c UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Compliance; Cost; Germany; Hypertension; Persistence

Indexed keywords

AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCHLOROTHIAZIDE;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; COMBINATION CHEMOTHERAPY; DRUG COST; FEMALE; GENERAL PRACTICE; GERMANY; HEALTH INSURANCE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PATIENT COMPLIANCE; PRESCRIPTION;

AGED; ANTIHYPERTENSIVE AGENTS; DRUG COSTS; FEMALE; GERMANY; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MIDDLE AGED; PATIENT COMPLIANCE;

EID: 84856058253     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2011.635229     Document Type: Article

References (49)

1. World Health Organization. Prevention of cardiovascular disease: guideline for assessment and management of cardiovascular risk. 2007. Available at http://www.who.int/cardiovascular-diseases/guidelines/Full%20text.pdf Last accessed on November 2nd, 2011
2. Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004;43:10-17 (Pubitemid 38031904)
3. Prugger C, Heuschmann PU, Keil U. Epidemiologie der hypertonie in Deutschland und weltweit. Herz 2006;31:287-93 (Pubitemid 44046491)
4. WilleE, Scholze J, Alegria E, etal. Modelling the costs of care of hypertension in patients with metabolic syndrome and its consequences, in Germany, Spain and Italy. Eur J Health Econ 2011;12:205-18
5. Dickinson HO, Mason JM, Nicolson DJ, et al. Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials. J Hypertens 2006;24:215-33
6. Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Press 2009;18:308-47
7. Calhoun DA, Lacourciere Y, Chiang YT, et al. Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial. Hypertension 2009;54:32-9
8. Fox JC, Leight K, Sutradhar SC, et al. The JNC 7 approach compared to conventional treatment in diabetic patients with hypertension: a double-blind trial of initial monotherapy vs. combination therapy. J Clin Hypertens (Greenwich) 2004;6:437-42
9. Jamerson K, Bakris GL, Dahlof B, et al. Exceptional early blood pressure control rates: the ACCOMPLISH trial. Blood Press 2007;16:80-6 (Pubitemid 47050368)
10. Neutel JM. Fixed combination antihypertensive therapy. In: Oparil S, Weber MA, eds. Hypertension: a companion to Brenner and Rector's the Kidney. 2nd edn. Philadelphia, PA: Elsevier, 2005. p 522-9
11. Neutel JM, Smith DH, Weber MA, et al. Efficacy of combination therapy for systolic blood pressure in patients with severe systolic hypertension: the Systolic Evaluation of Lotrel Efficacy and Comparative Therapies (SELECT) study. J Clin Hypertens (Greenwich) 2005;7:641-6
12. Neutel JM. Prescribing patterns in hypertension: the emerging role of fixed-dose combinations for attaining BP goals in hypertensive patients. Curr Med Res Opin 2008;24:2389-401
13. Smith TR, Philipp T, Vaisse B, et al. Amlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: subgroup analyses of 2 randomized, placebo-controlled studies. J Clin Hypertens (Greenwich) 2007;9:355-64
14. Mancia G, De BG, Dominiczak A, et al. 2007 ESH-ESC practice guidelines for the management of arterial hypertension: ESH-ESC task force on the management of arterial hypertension. J Hypertens 2007;25:1751-62 (Pubitemid 47356612)
15. Deutsche Hochdruckliga e.V. DHL®. Deutsche Gesellschaft fur Hypertonie und Prävention. Leitlinien zur Behandlung der arteriellen Hypertonie. 2008. Available at http://www.awmf.org/uploads/tx-szleitlinien/046- 001-S2- Behandlung-der-arteriellen-Hypertonie-06-2008-06-2013.pdf Last accessed November 2, 2011
16. Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007; 120:713-9 (Pubitemid 47176510)
17. Brixner DI, Jackson KC, Sheng X, et al. Assessment of adherence, persistence, and costs among valsartan and hydrochlorothiazide retrospective cohorts in free-and fixed-dose combinations. Curr Med Res Opin 2008;24:2597-607
18. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 2010;55:399-407
19. Jackson KC, Sheng X, Nelson RE, et al. Adherence with multiple-combination antihypertensive pharmacotherapies in a US managed care database. Clin Ther 2008;30:1558-63
20. Sicras Mainar A, Galera Llorca J, Muñoz Ortí G, et al. Influence of compliance on the incidence of cardiovascular events and health costs when using single-pill fixed-dose combinations for the treatment of hypertension. Med Clin (Barc) 2011;136:183-91
21. Yang W, Chang J, Kahler KH, et al. Evaluation of compliance and health care utilization in patients treated with single pill vs. free combination antihyper-tensives. Curr Med Res Opin 2010;26:2065-76
22. Zeng F, Patel BV, Andrews L, et al. Adherence and persistence of single-pill ARB/CCB combination therapy compared to multiple-pill ARB/CCB regimens. Curr Med Res Opin 2010;26:2877-87
23. Erkens JA, Panneman MM, Klungel OH, et al. Differences in antihypertensive drug persistence associated with drug class and gender: a PHARMO study. Pharmacoepidemiol Drug Saf 2005;14:795-803 (Pubitemid 41684472)
24. Hasford J, Mimran A, Simons WR. A population-based European cohort study of persistence in newly diagnosed hypertensive patients. J Hum Hypertens 2002;16:569-75 (Pubitemid 35021364)
25. Hasford J, Schroder-Bernhardi D, Rottenkolber M, et al. Persistence with antihypertensive treatments: results of a 3-year follow-up cohort study. Eur J Clin Pharmacol 2007;63:1055-61 (Pubitemid 47561800)
26. Patel BV, Remigio-Baker RA, Mehta D, et al. Effects of initial anti-hypertensive drug class on patient persistence and compliance in a usual-care setting in the United States. J Clin Hypertens (Greenwich) 2007;9:692-700
27. Bramlage P, Hasford J. Blood pressure reduction, persistence and costs in the evaluation of antihypertensive drug treatment-a review. Cardiovasc Diabetol 2009;8:18
28. Hughes D, Cowell W, Koncz T, et al. Methods for integrating medication compliance and persistence in pharmacoeconomic evaluations. Value Health 2007;10:498-509 (Pubitemid 350013268)
29. Destro M, Cagnoni F, D'Ospina A, et al. New strategies and drugs in the treatment of hypertension: monotherapy or combination? Recent Pat Cardiovasc Drug Discov 2010;5:69-81
30. Erdine S. Compliance with the treatment of hypertension: the potential of combintation therapy. J Clin Hypertens (Greenwich) 2010;12:40-6
31. Patel BV, Remigio-Baker RA, Thiebaud P, et al. Improved persistence and adherence to diuretic fixed-dose combination therapy compared to diuretic monotherapy. BMC Fam Pract 2008;9:61
32. Schmieder RE. The role of fixed-dose combination therapy with drugs that target the renin-angiotensin system in the hypertension paradigm. Clin Exp Hypertens 2010;32:35-42
33. Schrader J, Bramlage P, Luders S, et al. BP goal achievement in patients with uncontrolled hypertension: results of the treat-to-target post-marketing survey with irbesartan. Clin Drug Investig 2007;27:783-96 (Pubitemid 47529294)
34. Becher H, Kostev K, Schroder-Bernhardi D. Validity and representativeness of the "Disease Analyzer" patient database for use in pharmacoepidemiolo-gical and pharmacoeconomic studies. Int J Clin Pharmacol Ther 2009; 47:617-26
35. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health 2008;11:44-7 (Pubitemid 351160875)
36. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol 1997;50:105-16 (Pubitemid 27089212)
37. Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocar-dial infarction. JAMA 2007;297:177-86 (Pubitemid 46089734)
38. Schmieder RE, Schwertfeger M, Bramlage P. Significance of initial blood pressure and comorbidity for the efficacy of a fixed combination of an angio-tensin receptor blocker and hydrochlorothiazide in clinical practice. Vasc Health Risk Manag 2009;5:991-1000
39. Bloom BS. Continuation of initial antihypertensive medication after 1 year of therapy. Clin Ther 1998;20:671-81 (Pubitemid 28421488)
40. Degli EE, Sturani A, Di MM, et al. Long-term persistence with antihypertensive drugs in new patients. J Hum Hypertens 2002;16:439-44 (Pubitemid 34685595)
41. Elliott WJ, Plauschinat CA, Skrepnek GH, et al. Persistence, adherence, and risk of discontinuation associated with commonly prescribed antihypertensive drug monotherapies. J Am Board Fam Med 2007;20:72-80 (Pubitemid 46219403)
42. Hoer A, Gothe H, Khan ZM, et al. Persistence and adherence with antihyper-tensive drug therapy in a German sickness fund population. J Hum Hypertens 2007;21:744-6 (Pubitemid 47335306)
43. Mathes J, Kostev K, Gabriel A, et al. Relation of the first hypertension-associated event with medication, compliance and persistence in naive hypertensive patients after initiating monotherapy. Int J Clin Pharmacol Ther 2010;48:173-83
44. Jones DW, Hall JE. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure and evidence from new hypertension trials. Hypertension 2004;43:1-3 (Pubitemid 38031902)
45. Hess G, Hill J, Lau H, et al. Medication utilization patterns and hypertension-related expenditures among patients who were switched from fixed-dose to free-combination antihypertensive therapy. Pharmacy and Therapeutics 2008;33:652-66
46. Maronde RF, Chan LS, Larsen FJ, et al. Underutilization of antihypertensive drugs and associated hospitalization. Med Care 1989;27:1159-66
47. Paramore LC, Halpern MT, Lapuerta P, et al. Impact of poorly controlled hypertension on healthcare resource utilization and cost. Am J Manag Care 2001;7:389-98 (Pubitemid 32321923)
48. Rizzo JA, Simons WR. Variations in compliance among hypertensive patients by drug class: implications for health care costs. Clin Ther 1997; 19:1446-57 (Pubitemid 28133280)
49. Sokol MC, McGuigan KA, Verbrugge RR, et al. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005;43:521-30 (Pubitemid 40847288)